Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.45 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.43 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.43 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.43 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172837 | 0.85 | TRPV1 (0.51) | PYGLTRPV1CNR1PLAAT3PLAAT5 | |
| SCHEMBL4173472 | 0.84 | PYGL (0.60) | PYGLTRPV1CNR1KCNH2PLAAT3 | |
| SCHEMBL4181751 | 0.84 | PYGL (0.59) | PYGLTRPV1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4171377 | 0.83 | PLAAT3 (0.47) | CNR1PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL4181267 | 0.82 | PLAAT3 (0.46) | CNR1PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL4181644 | 0.82 | PLAAT3 (0.57) | CNR1PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL4185070 | 0.82 | PYGL (0.59) | PYGLTRPV1CNR1KCNH2PLAAT3 | |
| SCHEMBL4174195 | 0.81 | CNR1 (0.50) | PYGLTRPV1CNR1PLAAT3PLAAT5 | |
| SCHEMBL4170552 | 0.80 | PYGL (0.57) | PYGLTRPV1CNR1KCNH2PLAAT3 | |
| SCHEMBL4178958 | 0.78 | PYGL (0.58) | PYGLTRPV1KCNH2PLAAT3PLAAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | GRUNENTHAL GMBH (DE) | 2009-07-16 | — | — | US | claimed |
| EP-1968935-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | claimed |
| WO-2007079958-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | GRUNENTHAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-1968935-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079958-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | FHIT, CYP3A43, DNPEP | PYGL 422/4885TRPV1 1259/4885CNR1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.